KPV

Anti-Inflammatory Tripeptide · Alpha-MSH Fragment

Overview

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.

Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.

Reduces TNF-α and IL-6 through NF-κB pathway inhibition.

May help balance overactive immune responses in autoimmune conditions.

Potential benefits for inflammatory arthritis through cytokine reduction.

Demonstrated benefit in Crohn's disease and ulcerative colitis models.

Mechanism

Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.

Reduces TNF-α and IL-6 through NF-κB pathway inhibition.

Research areas

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.
Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.
Reduces TNF-α and IL-6 through NF-κB pathway inhibition.
May help balance overactive immune responses in autoimmune conditions.
Potential benefits for inflammatory arthritis through cytokine reduction.
Demonstrated benefit in Crohn's disease and ulcerative colitis models.
Helps restore intestinal barrier function.
Selective antimicrobial activity preserves beneficial gut bacteria.
Topical KPV reduced psoriatic markers by 60% and improved skin barrier function.
Reduces inflammatory skin conditions without systemic effects.

Research notes

Minimal to no side effects reported
Does not cause immunosuppression like steroids
No melanin production/tanning effects
May temporarily reduce inflammation-related symptoms
Signs of infection (fever, chills) - very rare
Severe injection site reactions
Paradoxical inflammation increase
Allergic reaction symptoms
Unusual fatigue or weakness
Known peptide allergies
Active severe infections (theoretical)
Pregnancy or breastfeeding (limited data)

AXIOM catalogue

KPV — research-use catalogue record with strengths and available batch details where listed.

References

FAQs

Is KPV the same as alpha-MSH or melanotan?

No. KPV is the C-terminal tripeptide fragment of alpha-MSH, not the full hormone. Unlike melanotan, KPV provides anti-inflammatory benefits without causing melanin production or tanning. It's inflammation-focused, not pigmentation-focused.

Can I take KPV orally?

Yes. KPV is one of the few peptides with demonstrated oral bioavailability. It's transported into intestinal cells via PepT1 transporters, making oral capsules or dissolved powder viable alternatives to injection for gut health applications.

How quickly does KPV reduce inflammation?

Effects appear quickly—many users notice reduced inflammation within 1-3 days of starting. By week 1-2, inflammatory symptoms (joint pain, swelling, gut issues) typically show noticeable improvement. Full effects across inflammatory markers appear by week 4-6.

Can I use KPV for autoimmune conditions?

KPV shows promise for autoimmune modulation by reducing pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression. It may help balance overactive immune responses in conditions like Crohn's disease, but requires medical supervision and cannot replace standard treatments.